By Blair Childs, Senior Vice President, Public Affairs
Today’s comprehensive 100-day supply chain assessment for pharmaceuticals and active pharmaceutical ingredients (APIs) provides a needed and important step forward in addressing vulnerabilities. Premier appreciates the Administration’s recognition that creating a resilient pharmaceutical supply chain requires 1) ongoing public-private sector engagement; 2) segment specific solutions due to the unique nature of the pharmaceutical supply chain; 3) upstream visibility and transparency into the source of ingredients and manufacturing sites; and 4) identification of financial incentives beyond use of the Defense Production Act to help drive private sector willingness to develop domestic production capacity.
No organization has done more than Premier to eliminate drug shortages and create a healthy marketplace. It is in our economic interest to have every product possible on contract and available at competitive prices. Premier is also developing new supplier relationships to encourage increased domestic capacity in the market for both APIs and finished drugs, driving more supply consistency and reduced prices through greater competition.
Premier has brought more than 150 shortage drugs to market, and has successfully protected supply even as demand surged more than 150 percent during the pandemic. Our efforts have paid off as eight products added to ProvideGx have since been delisted from the FDA drug shortage list.
Premier looks forward to working alongside the Administration, Congress, and other stakeholders to action the recommendations in today’s report and create a resilient and sustainable pharmaceutical supply chain.